Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine
Three months after winning the FDA’s breakthrough therapy designation for its bigger/better pneumococcal conjugate vaccine candidate aimed at toppling Pfizer’s Prevnar 13 megablockbuster bestseller, Merck is back with a batch of upbeat Phase II data from their big clinical program.
In a nutshell, Merck researchers say that V114 proved non-inferior to Prevnar 13 on the lineup of pneumococcus strains it guards against — while also illustrating its effectiveness to boot up an immune response against two additional disease-causing serotypes, 22F and 33F, not covered by the Pfizer vaccine.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters